玻璃体内注射Lucentis治疗中心性渗出性脉络膜视网膜病变的临床疗效

目的　评价玻璃体内注射Ｌｕｃｅｎｔｉｓ治疗中心性渗出性脉络膜视网膜病变（ｃｅｎｔｒａｌｅｘｕｄａｔｉｖｅｃｈｏｒｉｏｒｅｔｉｎｏｐａｔｈｙ,ＣＥＣ）的临床疗效。方法　ＣＥＣ所致黄斑部脉络膜新生血管（ｃｈｏｒｏｉｄａｌｎｅｏｖａｓｃｕｌａｒｉｚａｔｉｏｎ,ＣＮＶ）患眼３２例,对比分析单次玻璃体内注射Ｌｕ-ｃｅｎｔｉｓ治疗前后最佳矫正视力（ｂｅｓｔｃｏｒｒｅｃｔｅｄｖｉｓｕａｌａｃｕｉｔｙ,ＢＣＶＡ）、光学相干断层扫描（ｏｐｔｉｃａｌｃｏｈｅｒｅｎｃｅｔｏｍｏｇｒａｐｈｙ,ＯＣＴ）及荧光素钠血管造影（ｆｕｎｄｕｓｆｌｕｏｒｅｓｃｅｉｎａｎｇｉｏｇｒａｐｈｙ,ＦＦＡ）的变化。结果　玻璃体内注射Ｌｕｃｅｎｔｉｓ治疗前与治疗后１周、１个月和３个月ＢＣＶＡ分别为０．７２±０．０７、０．６８±０．１６、０．３９±０．１０、０．１５±０．０８;黄斑中心厚度（ｆｏｖｅａｃｅｎｔｒａｌｉｓｔｈｉｃｋｎｅｓｓ,ＣＭＴ）分别为（４３９２０±１０１．１６）μｍ、（３２１．１０±９８．２０）μｍ、（２５７．３５±６９．８５）μｍ、（２６７．５２±６５．３７）μｍ。玻璃体内注射Ｌｕｃｅｎｔｉｓ治疗后１周、１个月和３个月,ＢＣＶＡ显著提高,ＣＭＴ显著降低,与治疗前相比差异均有显著统计学意义（均为Ｐ＞０．０１）;治疗后１个月、３个月分别与治疗后１周相比,ＢＣＶＡ显著提高,ＣＭＴ显著降低,差异均有显著统计学意义（均为Ｐ＜０．０１）;治疗后１个月和３个月间相比,ＢＣＶＡ、ＣＭＴ变化差异均无统计学意义（均为Ｐ＞０．０５）。ＦＦＡ检查显示:治疗后１周:ＣＮＶ病灶渗漏停止或渗漏减少者２１眼（６５．６３％）,持续渗漏１１眼（３４．３８％）;治疗后１个月:ＣＮＶ病灶渗漏停止或渗漏减少者２８眼（８７５０％）,持续渗漏４眼（１２５０％）;治疗后３个月:ＣＮＶ病灶渗漏停止或渗漏减少者２７眼（８４．３８％）,持续渗漏５眼（１５．６３％）,１眼（３．１３％）出现渗漏复发。结论　玻璃体内注射Ｌｕｃｅｎｔｉｓ治疗可以在短期内部分或完全封闭ＣＥＣ所致的ＣＮＶ,减轻黄斑水肿、提高ＢＣＶＡ,为ＣＥＣ的临床治疗提供了新的思路,但其长期效果有待进一步观察。     

雷珠单抗玻璃体腔注射治疗脉络膜新生血管的OCT分析

目的 分析评价雷珠单抗(Ranibizumab,商品名Lucentis)玻璃体内注射治疗脉络膜新生血管(CNV)的光学相干断层扫描(OCT)结果.方法 采用小样本单中心回顾性研究.脉络膜新生血管患者20例(25眼),门诊确诊后玻璃体腔注射雷珠单抗0.5 mg(0.05 ml),注射后第1、2、3、6个月各随访1次,并在前2个月随访时再注射相同剂量2次.随访时主要检查最佳矫正视力、眼压、裂隙灯观察眼底、OCT检查黄斑中心凹视网膜厚度(CFT)等检查,研究分析患者治疗前后眼底OCT的变化.结果 注射雷珠单抗后视力较注射前平均提高:1月(1.43±2.11)行,2月(1.53±2.48)行,3月(1.87±2.29)行,6月(1.67±2.58)行.注射雷珠单抗后的每次随访最佳矫正视力和首次治疗前相比,差异均有统计学意义(P＜0.05).首次注射雷珠单抗治疗后各时间段间的视力差异无统计学意义(P＞0.05).注射雷珠单抗后OCT显示的CFT分别为:1月为301.22±22.93 μm,2月为290.17±18.35μm,3月为272.84±31.26 μm,6月为262.54±26.82μm.术后1、2、3、6个月随访的CFT与术前对比明显减小,具有统计学差异(P＜0.05).结论 CNV患者玻璃体腔内注射雷珠单抗,可有效减轻黄斑水肿,提高视力,是有效方法之一.     

雷珠单抗治疗息肉状脉络膜血管病变的疗效观察

目的：比较玻璃体腔内注射雷珠单抗在不同类型的息肉状脉络膜血管病变治疗中的临床疗效。
　　方法：选取2013-05/2015-05在绍兴市人民医院治疗的63例63眼息肉状脉络膜血管病变患者作为研究对象,根据息肉数的差异分为单息肉组(38例38眼)和多息肉组(25例25眼),两组患者均接受玻璃体腔内注射雷珠单抗治疗,每月1次,连续注射3mo。注射后随访1a,比较两组患者治疗后最佳矫正视力( best corrected visual acuity, BCVA)和中心视网膜厚度( central retinal thickness,CRT)的变化。
　　结果：与多息肉组比较,单息肉组治疗前最大线性直径更大、纤维血管性视网膜色素上皮脱离发生率更低、BCVA更低(P<0.05)。治疗后3、6mo,1a单息肉组BCVA明显低于多息肉组(P<0.05);单息肉组治疗后3、6mo,1a时BCVA较治疗前均显著下降( P<0.05)。单息肉组和多息肉组患者的CRT在治疗后6、12mo有统计学差异(P<0.05);单息肉组治疗后3、6mo,1a时CRT均较治疗前低( P<0.05),多息肉组治疗后3、6 mo的CRT较治疗前低( P<0.05)。结论：玻璃体腔内注射雷珠单抗在多息肉型息肉状脉络膜血管病变中治疗效果更好,息肉数量对于评估预后具有重要意义。     

玻璃体腔注射雷珠单抗治疗非AMD脉络膜新生血管

目的：临床观察雷珠单抗( ranibizulab )治疗非年龄相关性黄斑变性( age-related lacular degeneration,AMD)脉络膜新生血管患者的疗效。
　　方法：回顾性分析2011-07/2015-04间在我院玻璃体腔注射ranibizulab治疗非AMD脉络膜新生血管的疗效及眼部与全身不良反应。治疗前后均进行裂隙灯的检查、最佳矫正视力的测定、荧光素眼底血管造影( fluorescein fundus angiography, FFA)、光学相干性断层扫描( optical coherence tolography,OCT),治疗后分别观察注射次数及术前和术后(末次随访时)患者的最佳矫正视力、黄斑区1 ll直径视网膜最大厚度。
　　结果：随访6lo~3a,治疗后平均视力(4.77±0.24)与治疗前(4.50±0.34)相比差异具有统计学意义(P<0.01),黄斑区1 ll直径最大厚度(317.62±55.05μl )较术前(421.63±139.37μl )相比差异具有统计学意义( P<0.01)。平均治疗次数为2.6±1.3次。患眼治疗后均未发生眼内炎、青光眼、视网膜脱离、葡萄膜炎等并发症及全身不良反应。
　　结论：Ranibizulab治疗非AMD脉络膜新生血管有效、不良反应低。     

玻璃体腔注射贝伐单抗治疗增生性糖尿病视网膜病变

糖尿病视网膜病变（diabetic retinopathy,DR）是糖尿病的严重并发症,尤其是增生性糖尿病视网膜病变（proliferative diabetic retinopathy,PDR）是工作年龄人群中首位致盲性眼病.近年来采用血管内皮生长因子抑制剂贝伐单抗（Bevacizumab,商品名Avastin）治疗PDR取得一定成效,其可促进玻璃体积血吸收,视网膜新生血管消退,减轻黄斑水肿,降低视网膜脱离的发生率,甚至使PDR患者避免玻璃体手术.     

玻璃体腔注射雷珠单抗联合地塞米松缓释剂治疗视网膜静脉阻塞继发黄斑水肿

目的：比较玻璃体腔注射地塞米松缓释剂(Ozurdex)联合雷珠单抗治疗视网膜静脉阻塞继发黄斑水肿(RVO-ME)与单独使用雷珠单抗治疗的疗效及安全性的差异。方法：选取2020-06/2022-12就诊于我院经眼底血管荧光造影检查确诊为非缺血型RVO-ME的患者，所有患者先行玻璃体腔注射0.5 mg雷珠单抗注射液，2 wk后复查黄斑中心凹视网膜厚度(CRT)≥300 μm的42例42眼患者纳入研究，随机分为联合治疗组(21例21眼，即时给予玻璃体腔内注射地塞米松缓释剂)及单药治疗组[21例21眼，仍继续按3+按需(PRN)方式行雷珠单抗注射治疗]。观察治疗前及分组治疗后2 wk，1、2、3、4、5、6 mo的最佳矫正视力(BCVA)、CRT及眼压的改变，并观察眼部及全身并发症的发生情况。结果：分组治疗后2 wk，1、2、3、4、5、6 mo，两组患者BCVA及CRT的改善程度较治疗前显著好转(均P&#x003C;0.01)； 治疗后2、3 mo，两组间BCVA及CRT比较有差异(均P&#x003C;0.05)，治疗后2 mo时联合治疗组BCVA字母数增加最明显。单药治疗组黄斑水肿平均复发时间为1.45±0.53 mo，雷珠单抗注射平均4.21±0.78次，两组患者治疗后均未见严重并发症。联合治疗组最常见的并发症为结膜下出血和眼压升高，局部使用降压药后眼压可控制，没有患者需接受抗青光眼及白内障手术。结论：玻璃体腔注射地塞米松缓释剂联合雷珠单抗治疗RVO-ME与单独使用雷珠单抗治疗相比，能显著提高患者的视力，有效减轻黄斑水肿，疗效持续时间长，可有效减少玻璃体腔注药次数。     

玻璃体视网膜手术联合玻璃体腔注射康柏西普或雷珠单抗治疗严重PDR的临床观察

背景 玻璃体视网膜手术(VRS)是治疗严重增生性糖尿病视网膜病变(PDR)的重要手段,术前行玻璃体腔注射抗血管内皮生长因子(VEGF)药物辅助VRS治疗PDR已在临床上广泛应用,但不同抗VEGF药物对VRS辅助作用的差异尚不清楚. 目的 观察术前玻璃体腔注射抗VEGF药物对严重PDR患眼行VRS治疗效果的影响,并比较康柏西普和雷珠单抗2种不同抗VEGF药物对VRS辅助作用的差异.方法 采用回顾性病例对照研究.收集2014年10月至2016年1月就诊于天津市眼科医院并确诊为严重PDR行微创玻璃体切割术治疗的患者96例98眼的临床资料.根据VRS术前3d是否注射抗VEGF药物将患者分为术前玻璃体腔注射康柏西普(IVC)治疗组31例32眼、术前玻璃体腔注射雷珠单抗(IVR)治疗组30例31眼和单纯VRS治疗组35例35眼,3个组患者基线特征比较,差异均无统计学意义(均P＞0.05).所有手术均由同一名医生完成,观察并记录3个组患眼玻璃体切割手术时间、术中电凝使用、严重出血及医源性裂孔发生情况.手术后随访3～6个月,平均随访(3.51±0.59)个月,对比分析3个组患眼最佳矫正视力(BCVA)变化及术后并发症发生情况.结果 术前IVC治疗组、术前IVR治疗组和单纯VRS治疗组患眼平均手术时间分别为(84.84±11.03)、(83.45±14.24)、(104.57±13.42) min,术前IVC治疗组、术前IVR治疗组平均手术时间较单纯VRS治疗组明显缩短,差异均有统计学意义(t=6.622、6.604,均P＜0.01).术前IVC治疗组和术前IVR治疗组患眼术中电凝使用率分别为31.25％和29.03％,均显著低于单纯VRS治疗组的60.00％,差异均有统计学意义(x2=5.558,P=0.018;x2 =6.359,P=0.012).术前IVC治疗组、术前IVR治疗组和单纯VRS治疗组术中严重出血发生率分别为15.63％、12.90％和42.86％,术前IVC治疗组和术前IVR治疗组术中严重出血发生率较单纯VRS治疗组明显降低,差异均有统计学意义(x2=5.920,P=0.015;x2=7.195,P=0.007).术前IVC治疗组和术前IVR治疗组术中医源性裂孔发生率及术后玻璃体腔再出血、一过性高眼压、视网膜再脱离及新生血管性青光眼发生率比较,差异均无统计学意义(均P＞0.05).3个组患眼术前及术后3个月BCVA总体比较,差异均有统计学意义(F分组=4.077,P=0.020;F时间=100.937,P=0.000).术前IVC治疗组、术前IVR治疗组和单纯VRS治疗组患眼术后3个月BCVA分别为0.80±0.37、0.82±0.32和1.03±0.52,均较术前显著提高,差异均有统计学意义(均P＜0.01).术前IVC治疗组和术前IVR治疗组术后平均BCVA均较单纯VRS治疗组提高,差异均有统计学意义(均P＜0.05). 结论 严重PDR患眼VRS前行玻璃体腔注射抗VEGF药物可缩短平均手术时间,减少术中出血和电凝使用率,并提高患眼BCVA.玻璃体腔注射康柏西普和雷珠单抗对VRS治疗严重PDR的辅助效果相似.     

氪激光治疗中心性渗出性脉络膜视网膜病变

目的：评价氪黄激光治疗中心性渗出性脉络膜视网膜病变(central exudative chorioretinphathy，CECR)的临床效果。方法：应用美国HGM公司氪黄激光治疗中心性渗出性脉络膜视网膜病变活动期病灶38例(38眼)，并分别于治疗后1、3、6、12月眼底荧光血管造影复查。结果：38例中36例患者一次性光凝治愈，新生血管膜消失，随访无复发。其中22例视力提高2～6行；14例保持原有视力；2例视力下降，治愈率达94．70％。结论：氪黄激光治疗中心性渗出性脉络膜视网膜病变，是一种安全有效、简便经济的治疗方法。     

23G微创玻璃体切割术联合雷珠单抗玻璃体腔注射治疗PDR

目的:观察23G微创玻璃体切割术联合雷珠单抗玻璃体腔注射治疗增生性糖尿病视网膜病变(PDR)的临床效果。方法:回顾性研究。采集2016-01/2020-01医院收治的PDR患者78例89眼,按术前是否给予雷珠单抗玻璃体腔注射治疗分为手术组(仅行23G微创玻璃体切割术,35例41眼)与联合组(23G微创玻璃体切割术联合术前玻璃体腔注射雷珠单抗治疗,43例48眼),比较两组手术时间、术中出血、术中电凝止血次数、眼内填充及视网膜裂孔发生情况;治疗前,术后1d,3mo最佳矫正视力(BCVA)、眼压、黄斑中心凹厚度(CMT)、视网膜新生血管荧光素渗漏面积的变化;治疗前、术后1wk均抽取房水测定血管内皮生长因子(VEGF)-A、人基质细胞衍生因子-1(SDF-1)、色素上皮衍生因子(PEDF)含量的变化;统计两组随访3mo手术并发症发生率。结果:联合组手术时间短于手术组,电凝止血次数、硅胶填充眼数少于手术组(P<0.05),术中总出血眼数少于手术组(P<0.05);术后1d,3mo联合组BCVA改善优于手术组(P<0.05),CMT、视网膜新生血管渗漏面积低于手术组(P<0.05);两组眼压比较无差异(P>0.05);术后1wk,两组VEGF-A、SDF-1、PEDF均降低(P<0.001),联合组房水内VEGF-A、SDF-1、PEDF均低于手术组(P<0.001);联合组医源性裂孔及玻璃体再积血发生率低于手术组(P<0.05),其余各并发症均无差异(P>0.05)。结论:23G微创玻璃体切割术联合雷珠单抗玻璃体腔注射治疗PDR整体价值优于单独应用23G微创玻璃体切割术,可降低手术难度,缩短手术时间,减少术中出血及器械操作,促进术后视力恢复,抑制视网膜新生血管生成,降低医源性损伤发生风险,并发症少,更安全有效。     

雷珠单抗联合地塞米松缓释剂对糖尿病性白内障术后黄斑水肿的预防及视网膜、脉络膜厚度的影响

目的 探讨雷珠单抗联合地塞米松缓释剂对糖尿病性白内障术后黄斑水肿的预防及黄斑中心凹视网膜厚度和黄斑中心凹下脉络膜厚度的影响。方法 前瞻性随机对照研究。研究对象2020年6月至2022年1月收治于我院的112例(134只眼)糖尿病性白内障患者。随机数字表法将112例患者分为研究组(56例)和对照组(56例),两组患者均实施超声乳化白内障吸除术(PHACO)联合人工晶状体植入术(IOL)治疗。对照组使用地塞米松缓释剂进行玻璃体内注射治疗,研究组在对照组基础上给予雷珠单抗玻璃体腔注射治疗。比较两组患者手术前后平均最佳矫正视力(BCVA)、黄斑中心凹视网膜厚度、黄斑总容积、黄斑水肿发生情况和黄斑中心凹下脉络膜厚度。结果 两组患者术前基线资料比较差异均无统计学意义(均P>0.05);重复测量方差分析结果显示,两组患者平均BCVA、黄斑中心凹视网膜厚度、黄斑总容积和黄斑中心凹下脉络膜厚度术后不同时间点差异均有统计学意义(均P<0.05),不同组别之间差异有统计学意义(均P<0.05),不同时间与组别之间有交互作用(均P<0.05),且研究组患者手术后各项指标均低于对照组(均...     

Chorioretinal response to intravitreal aflibercept injection in acute central serous chorioretinopathy

AIM: To evaluate chorioretinal responses to intravitreal aflibercept injection (IAI) in patients with acute central serous chorioretinopathy (CSC). METHODS: Seventy-one eyes from 71 patients with symptomatic CSC for less than six months were included. Thirty-five eyes received a single IAI and 36 eyes were observed without treatment. Best-corrected visual acuity (BCVA), central subfield foveal thickness (CSFT), and subfoveal choroidal thickness (SFCT) were assessed at baseline and at 1, 2, and 3mo. RESULTS: The mean SFCT in the IAI group decreased at 1mo, rebounded at 2mo and remained stable at 3mo compared to the baseline, while significant change was not noted in the observation group. The mean CSFT decreased significantly during the 3-month study period in both groups, and was significantly lower in the IAI group at 1mo (P<0.001). A rebound of CSFT between 1 and 2mo was noted in 14 eyes (40.0%) in the IAI group and in 1 eye (2.8%) in the observation group (P<0.001). The significant visual improvement was achieved from 1mo in the IAI group, and from 2mo in the observation group. The rate of complete absorption of subretinal fluid at 3mo did not differ between the two groups. (45.7% vs 41.7%, P=0.813). CONCLUSION: A single IAI for acute CSC induce a transient decrease in SFCT and CSFT, which implies that IAI may have a pharmacological effect on the underlying hyperpermeable choroid in acute CSC.     

光动力疗法治疗中心性渗出性脉络膜视网膜病变的临床观察

目的:评价光动力疗法(photodynamic therapy,PDT)对中心性渗出性脉络膜视网膜病变(central exudative chorioreti-nopathy,CEC)的临床疗效观察。方法:回顾36例36眼经眼底检查、荧光血管造影检查(fundus fluorescein angiorgam,FFA)和吲哚青绿眼底血管造影检查(indocyanine green angiography,ICGA)确诊为CEC的患者,36眼接受PDT治疗前后,对比分析治疗前后的临床资料,观察PDT治疗的有效性和安全性。结果:PDT治疗后视力明显改善者20眼(55.6%),视力稳定者14眼(38.9%),还有2眼(5.5%)视力下降。眼底检查发现病灶明显缩小,出血渗出吸收。FFA显示脉络膜新生血管(choroidal neovascularization,CNV)病灶闭合,只有1眼出现病灶扩大。结论:PDT治疗CEC在大多数患者是安全有效的。     

中心性渗出性脉络膜视网膜病变的光动力治疗

目的 观察光动力疗法（PDT）治疗中心性渗出性脉络膜视网膜病变的临床效果。方法 以眼底检查、视力、眼底荧光血管造影（FFA）、吲哚菁绿脉络膜血管造影（ICG）和光学相干断层成像技术（OCT）等影像学检查为观察指标，总结PDT治疗9例9眼中心性渗出性脉络膜视网膜病变后不同时间的随访结果，从而评价PDT治疗中心性渗出性脉络膜视网膜病变的安全性和有效性。结果 治疗后1周、1个月和3个月随访时，荧光渗漏完全消退者分别为7眼、5眼和3眼。对复发的4眼进行了二次治疗；二次治疗后随访2－5个月未见荧光渗漏复发。9眼中8眼视力不同程度提高，1眼无变化。治疗过程中和治疗后未发生任何不良反应。结论 光动力疗法治疗中心性渗出性脉络膜视网膜病变短期疗效满意、安全，对视力无损害。     

Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration

We report a series of retinal pigment epithelial (RPE) tears after intravitreal bevacizumab therapy for choroidal neovascularization associated with age-related macular degeneration (ARMD). Retinal pigment epithelial tears were estimated to occur at an incidence of 1.6% in this patient population at our institution. Ophthalmologists should be aware of this rare but serious finding associated with exudative macular degeneration therapy.     

Intravitreous injection of bevacizumab for chronic central serous chorioretinopathy

Background/PurposeTo evaluate the effect of intravitreal bevacizumab on subretinal fluid absorption in patients with chronic central serous chorioretinopathy (CSCR).Materials and methodsThis was a retrospective case series study. Patients with CSCR symptoms for > 3 months and who received intravitreal injection of bevacizumab were included. Ocular examinations were carried out at baseline and every follow-up visit, including visual acuity, fundus examination, and optic coherence tomography.ResultsTwelve eyes in 12 patients were included in this study. One month after injection, three of the 12 patients who had increased central macular thickness were considered nonresponders. Nine of the 12 patients who had decreased central macular thickness were considered to have responded to intravitreal bevacizumab injection. The response rate was 75%. In the response group, the mean central macular thickness significantly decreased, from 306.7 ± 77.8 μm to 204.3 ± 59.3 μm (p = 0.001) at 1 month. The mean Logarithm of the Minimum Angle of Resolution (logMAR) visual acuity was significantly improved from 0.72 ± 0.35 to 0.50 ± 0.28 (p = 0.008). Six of these nine patients had stable conditions lasting > 6 months. Three of them had recurrence.ConclusionIntravitreal bevacizumab injections improved subretinal fluid absorption in some patients with CSCR. It could be an alternative therapy for patients with CSCR, especially when they are not suitable for other treatments.     

经瞳孔温热疗法治疗中心性渗出性脉络膜视网膜病变的初步观察

目的:探讨经瞳孔温热疗法(transpupillary thermotherapy,TTT)治疗中心性渗出性脉络膜视网膜病变(central exudative chorioretinopathy,CEC)的临床效果.方法:对眼底荧光素血管造影(fundus fluorescein angiography,FFA)和吲哚青绿血管造影(indo cyanine green angiography,ICGA)检查确诊的CEC患者的18只患眼进行TTT治疗.采用810nm半导体激光,光斑0.8～2.O mm,照射时间60s,能量80～300 mW,对FFA和ICGA图像所显示的脉络膜新生血管(choroidal neo vascularization,CNV)进行照射,照射区未出现颜色变化.对比分析患者治疗前后的视力、眼底、FFA结果.结果:治疗后视力提高者6眼,占33%;无变化者12眼,占67%.自觉症状有程度不同的改善者16眼,眼底检查病变减轻者10眼.13眼复查眼底血管造影,其中8眼脉络膜新生血管(choroidalneovascularization,CNV)明显消退、渗漏减轻.结论:TTT治疗CEC效果良好,值得临床推广应用.     

Macular hole after intravitreal ranibizumab injection for polypoidal choroidal vasculopathy

A 67‐year‐old man visited the clinic presenting with the complaint of decreased vision in his left eye. Visual acuity of the left eye was 6/6. On fundus examination, an orange polypoidal lesion and retinal pigment epithelial (RPE) detachment were seen. Fluorescein angiography and indocyanine green angiography were performed. There was hyperfluorescence of a clustered polyp‐like lesion. The patient was diagnosed with polypoidal choroidal vasculopathy and we recommended that he be seen again in three months. At this visit, visual acuity of the left eye had decreased to 6/9 and the RPE detachment was aggravated. Intravitreal injection of ranibizumab was performed. One month after the injection, visual acuity of his left eye was 6/96. A macular hole was seen in his left eye and vitrectomy of the left eye was performed. Optical coherence tomography was checked and it showed that the macular hole was closed. Two more intravitreal ranibizumab injections were done on the left eye. Visual acuity of his left eye subsequently improved to 6/18.8.     

中心性渗出性脉络膜视网膜病变的经瞳孔温热治疗

目的 评价经瞳孔温热疗法（transpupillary thermotherapy,TTT)治疗中心性渗出性脉络膜视网膜病变（central exudative chorioretinopathy,CEC)的疗效。方法 对12例（12只眼）黄斑区具有脉络膜新生血管（choroidal neovascularization,CNV)的中心性渗出性脉络膜视网膜病变患者进行TTT治疗，并随访观察治疗前后视力、眼底、眼底荧光血管造影（fundus fluorescein angiography,FFA)及吲哚青绿眼底血管造影（indocyanine green angiography,ICGA)的变化。结果 12只眼中有3只眼进行了二次治疗，最终所有患者眼底出血渗出的情况均得到改善，眼底造影显示CNV缩小或闭塞，治疗后视力提高3只眼，稳定6只眼，下降3只眼。结论 经瞳孔温热疗法可以减少因脉络膜新生血管膜而引起的出血及渗出，加速疤痕化，对黄斑区CNV有一定的疗效，但对中心视力的恢复尚不理想。     

复方血栓通联合激光治疗CSCR的疗效观察

目的：探讨复方血栓通联合激光治疗中心性浆液性脉络膜视网膜病变( central serous chorioretinopathy,CSCR)的临床疗效。
　　方法：将我院治疗的181例中心性浆液性脉络膜视网膜病变患者随机分为治疗组91例和对照组90例,对照组行激光治疗,治疗组在激光治疗后口服复方血栓通;比较两组患者临床疗效、平均光敏感度和血清睾酮、雌激素水平。结果：治疗后3wk,治疗组总有效率为90.1%,对照组为72.2%,治疗组显著高于对照组(χ2=10.473,P=0.001);治疗后6wk,治疗组总有效率亦显著高于对照组(χ2=4.499,P=0.034)。治疗组治愈时间、视力恢复时间均显著少于对照组,平均光敏感度显著高于对照组,两组间相比差异具有统计学意义(P<0.05)。治疗后两组患者相关激素水平均显著降低,其中治疗组血清激素水平降低程度显著优于对照组,组间相比差异具有统计学意义(P<0.05)。
　　结论：复方血栓通联合激光治疗中心性浆液性脉络膜视网膜病变,能够显著提高疗效,缩短病程,有利于视功能恢复,值得临床推广。     

Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age‐related macular degeneration

Purpose: To assess the hemodynamic response of retinal arterioles and venules following a single intravitreal injection of ranibizumab in neovascular age‐related macular degeneration (NV‐AMD) patients and to assess the influence of the number of prior injections on this response. Methods: Fifteen NV‐AMD patients were prospectively recruited and grouped according to the dosage of ranibizumab previously received. Group 1 NV‐AMD patients (n = 7) had previously received 1.50 mg or less, and group 2 patients (n = 8) had received more than 1.50 mg in the study eye. A group of 12 non‐NV AMD patients were also recruited for control comparison. Vessel diameter, centreline blood velocity and blood flow were assessed with the Canon Laser Blood Flowmeter immediately prior to an injection and at a mean follow‐up of 37.7 and 36.7 days for group 1 and group 2 patients, respectively. Results: The NV‐AMD patients as a whole and the group 1 cohort had a significantly greater arteriolar diameter at baseline than the non‐NV AMD patients. There was a significant reduction in arteriolar diameter, velocity and blood flow in group 1 but not in group 2 NV‐AMD patients at follow‐up. There was only an insignificant decrease in measured parameters of the retinal venules. At follow‐up, there was no difference in the diameter, velocity or flow between AMD patients. Conclusion: Intravitreal ranibizumab treatment for NV‐AMD induces a reduction in arteriolar diameter, velocity, and blood flow in patients who have received <1.50 mg of ranibizumab.